Zomedica (ZOM) 10-Q 13 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 13, 2018
Document Information [Line Items]
Entity Registrant Name	Zomedica Pharmaceuticals Corp.
Entity Central Index Key	1,684,144
Trading Symbol	zom
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		94,796,209
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Ex Transition Period	true

Condensed Unaudited Interim Con

Condensed Unaudited Interim Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 526,817	$ 3,448,147
Prepaid expenses and deposits	1,481,673	786,273
Trade and other receivables	37,742	28,272
	2,046,232	4,262,692
Prepaid expenses and deposits	1,374,260	566,832
Property and equipment	756,823	371,157
Intangible assets	13,331	15,141
	4,190,646	5,215,822
Current liabilities:
Accounts payable and accrued liabilities	1,280,379	828,737
	1,280,379	828,737
Shareholders' equity:
Capital stock, authorized unlimited common shares without par value, issued and outstanding 94,596,209 common shares (2017 - 90,225,869)	25,373,456	18,244,659
Additional paid-in capital	1,388,916	1,768,526
Accumulated deficit	(23,852,105)	(15,626,100)
	2,910,267	4,387,085
	$ 4,190,646	$ 5,215,822

Condensed Unaudited Interim C_2

Condensed Unaudited Interim Consolidated Balance Sheets (Parentheticals) - $ / shares $ / shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Capital stock, unlimited common shares authorized	Unlimited	Unlimited
Capital stock, no par value (in dollars per share)	$ 0	$ 0
Capital stock, shares issued (in shares)	94,596,209	90,225,869
Capital stock, shares outstanding (in shares)	94,596,209	90,225,869

Condensed Unaudited Interim C_3

Condensed Unaudited Interim Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Expenses:
Research and development	$ 630,371	$ 465,495	$ 3,765,332	$ 1,586,179
General and administrative	834,570	1,350,726	3,243,232	2,926,361
Professional fees	293,484	246,192	1,001,886	942,385
Amortization	431	699	1,810	2,098
Depreciation	86,162	22,903	150,320	65,994
Loss from operations	1,845,018	2,086,015	8,162,580	5,523,017
Gain on settlement of liabilities				(5,000)
Loss on sale of equipment	69,382		69,382
Foreign exchange gain	(4,122)	(5,333)	(5,957)	(16,229)
Loss before income taxes	1,910,278	2,080,682	8,226,005	5,501,788
Income tax expense
Net loss and comprehensive loss	$ 1,910,278	$ 2,080,682	$ 8,226,005	$ 5,501,788
Weighted average number of common shares - basic and diluted (in shares)	94,514,905	88,844,534	92,534,667	86,708,499
Loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.09)	$ (0.06)

Condensed Unaudited Interim C_4

Condensed Unaudited Interim Consolidated Statements of Shareholders' Equity - USD ($)		Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016		83,964,569
Balance at Dec. 31, 2016		$ 10,189,973		$ 1,205,456	$ (7,561,028)	$ 3,834,401
Stock issuance for services (in shares)		43,613
Stock issuance for services		$ 45,000				45,000
Stock issuance for financing, net of costs (in shares)		4,405,373
Stock issuance for financing, net of costs		$ 6,516,650				6,516,650
Stock-based compensation				837,531		$ 837,531
Stock issued due to exercise of options (in shares)		925,000				925,000
Stock issued due to exercise of options		$ 130,354		(30,156)		$ 100,198
Net loss for the period					(5,501,788)	(5,501,788)
Balance (in shares) at Sep. 30, 2017		89,338,555
Balance at Sep. 30, 2017		$ 16,881,977		2,012,831	(13,062,816)	5,831,992
Balance (in shares) at Dec. 31, 2017		90,225,869
Balance at Dec. 31, 2017		$ 18,244,659		1,768,526	(15,626,100)	4,387,085
Stock issuance for services (in shares)	[1]	641,717
Stock issuance for services		$ 1,238,513	[1]			1,238,513
Stock issuance for financing, net of costs (in shares)	[2]	1,861,627
Stock issuance for financing, net of costs		$ 3,966,362	[2]			3,966,362
Stock-based compensation				7,288		$ 7,288
Stock issued due to exercise of options (in shares)		1,866,996				1,866,996
Stock issued due to exercise of options		$ 1,923,922		(386,898)		$ 1,537,024
Net loss for the period					(8,226,005)	(8,226,005)
Balance (in shares) at Sep. 30, 2018		94,596,209
Balance at Sep. 30, 2018		$ 25,373,456		$ 1,388,916	$ (23,852,105)	$ 2,910,267
[1]	On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.
[2]	On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

Condensed Unaudited Interim C_5

Condensed Unaudited Interim Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Cash flows used in operating activities:
Net loss for the period	$ (1,910,278)	$ (2,080,682)	$ (8,226,005)	$ (5,501,788)
Adjustments for
Depreciation	86,162	22,903	150,320	65,994
Amortization	431	699	1,810	2,098
Loss on sale of equipment	69,382		69,382
Stock issued for services			1,238,513	45,000
Stock-based compensation		675,940	7,288	837,531
Change in non-cash operating working capital
Trade and other receivable	11,885	(13,340)	(9,470)	(10,231)
Prepaid expenses	56,399	45,160	(191,365)	(15,239)
Deposits	(1,281,617)	34,228	(1,311,463)	(181,193)
Accounts payable and accrued liabilities	(403,423)	(128,106)	451,643	(351,134)
	(3,371,059)	(1,443,198)	(7,819,347)	(5,108,962)
Cash flows from financing activities:
Cash proceeds from financing		3,320,000	4,002,496	6,570,000
Cash received from stock option exercises	98,715	60,655	1,537,024	100,198
Cash paid on stock issuance costs	(12,328)	(19,226)	(36,135)	(53,350)
Repayments of shareholder loan				(6,726)
	86,388	3,361,429	5,503,385	6,610,122
Cash flows used in investing activities:
Investment in property and equipment	(467,675)	(4,775)	(605,368)	(164,576)
	(467,675)	(4,775)	(605,368)	(164,576)
Increase (decrease) in cash and cash equivalents	(3,752,346)	1,913,456	(2,921,330)	1,336,584
Cash and cash equivalents, beginning of period	4,279,163	2,649,808	3,448,147	3,226,680
Cash and cash equivalents, end of period	$ 526,817	$ 4,563,264	$ 526,817	$ 4,563,264

Note 1 - Nature of Operations a

Note 1 - Nature of Operations and Going Concern	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	1. Nature of operations and going concern Zomedica Pharmaceuticals Corp. (the “Company”) was incorporated on January 7, 2013 2.4 On April 21, 2016, 9674128 May 2, 2016 June 21, 2016, Zomedica has one 100 190, 48108 1250, 639 5th T2P 0M9. Going concern These condensed unaudited interim consolidated financial statements have been prepared on a going concern basis, which contemplates that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. Accordingly, they do not

Note 2 - Basis of Preparation

Note 2 - Basis of Preparation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Basis of Accounting [Text Block]	2. Basis of preparation The accounting policies set out below have been applied consistently in the condensed unaudited interim consolidated financial statements. Basis of consolidation These condensed unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned operating subsidiary, Zomedica Pharmaceuticals, Inc. All inter-company accounts and transactions have been eliminated on consolidation.

Note 3 - Significant Accounting

Note 3 - Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Significant accounting policies Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption. Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted. Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements. Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730. Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss. Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not nine September 30, 2018 Comprehensive loss The Company follows ASC topic 220. no Future accounting pronouncements In February 2016, No. 2016 02, 842 842 December 15, 2018.

Note 4 - Critical Accounting Ju

Note 4 - Critical Accounting Judgments and Key Sources of Estimation Uncertainty	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Critical Accounting Judgments and Key Sources of Estimation Uncertainly [Text Block]	4. Critical accounting judgments and key sources of estimation uncertainty The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not may The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. Critical areas of estimation and judgements in applying accounting policies include the following: Going concern These condensed unaudited interim consolidated financial statements have been prepared in accordance with U.S. GAAP on a going concern basis, which assumes the realization of assets and discharge of liabilities in the normal course of business within the foreseeable future. Management uses judgment in determining assumptions for cash flow projections, such as anticipated financing, anticipated sales and future commitments to assess the Company’s ability to continue as a going concern. A critical judgment is that the Company continues to raise funds going forward and satisfy their obligations as they become due. Useful lives of property and equipment As described in Note 3 nine September 30, 2018 September 30, 2017, not Deferred income taxes The calculation of deferred income taxes is based on assumptions which are subject to uncertainty as to timing and which tax rates are expected to apply when temporary differences reverse. Deferred tax recorded is also subject to uncertainty regarding the magnitude of non-capital losses available for carry forward and of the balances in various tax pools. By their nature, these estimates are subject to measurement uncertainty, and the effect on the financial statements from changes in such estimates in future period could be material. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets are reviewed at each balance sheet date and adjusted to the extent that it is no Stock-based payments The Company estimates the fair value of convertible securities such as options using the Black-Scholes option-pricing model which requires significant estimation around assumptions and inputs such as expected term to maturity, expected volatility and expected dividends.

Note 5 - Prepaid Expenses and D

Note 5 - Prepaid Expenses and Deposits	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Prepaid Rent [Text Block]	5. Prepaid expenses and deposits The Company entered into a lease agreement with Wickfield Phoenix LLC effective on August 23, 2016. $801,973 August 26, 2016 July 31, 2018 $1,269,073 one September 30, 2018, $509,380 December 31, 2017 - $155,220

Note 6 - Property and Equipment

Note 6 - Property and Equipment	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2016 $ 61,598 $ 7,364 $ 243,529 $ 25,672 $ 338,163 Additions 89,557 68,694 2,200 11,285 171,736 Balance at December 31, 2017 151,155 76,058 245,729 36,957 509,899 Additions 11,701 105,821 246,375 250,471 614,368 Disposals - - (139,466 ) (10,937 ) (150,403 ) Balance at September 30, 2018 162,856 181,879 352,638 276,491 973,864 Accumulated depreciation Balance at December 31, 2016 13,858 1,490 29,783 3,998 49,129 Depreciation 28,944 10,355 45,092 5,222 89,613 Balance at December 31, 2017 42,802 11,845 74,875 9,220 138,742 Depreciation 66,405 11,130 42,082 30,703 150,320 Disposals - - (61,546 ) (10,475 ) (72,021 ) Balance at September 30, 2018 109,207 22,975 55,411 29,448 217,041 109,207 22,975 55,411 29,448 217,041 Net book value as at: December 31, 2017 $ 108,353 $ 64,213 $ 170,854 $ 27,737 $ 371,157 September 30, 2018 $ 53,649 $ 158,904 $ 297,227 $ 247,043 $ 756,823 In August 2018, $462 $77,920 $9,000. $69,382.

Note 7 - Intangible Assets

Note 7 - Intangible Assets	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	7. Intangible assets Computer software Trademarks Total Cost Balance at December 31, 2016 $ 5,143 $ 16,236 $ 21,379 Additions - - - Balance at December 31, 2017 5,143 16,236 21,379 Additions - - - Balance at September 30, 2018 5,143 16,236 21,379 Accumulated amortization Balance at December 31, 2016 2,428 1,013 3,441 Amortization 1,715 1,082 2,797 Balance at December 31, 2017 4,143 2,095 6,238 Amortization 1,000 810 1,810 Balance at September 30, 2018 5,143 2,905 8,048 Net book value as at: December 31, 2017 $ 1,000 $ 14,141 $ 15,141 September 30, 2018 $ - $ 13,331 $ 13,331

Note 8 - Loan Arrangements

Note 8 - Loan Arrangements	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Loan arrangements On October 17, 2017, may $5,000,000, five 5 may one $250,000 one not two may fourteen 14% September 30, 2018, no

Note 9 - Capital Stock

Note 9 - Capital Stock	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Capital stock The Company is authorized to issue an unlimited number of common stock, all without par value. Issued and outstanding common stock: Capital Number stock Balance at December 31, 2016 83,964,569 $ 10,189,973 Stock issuance for services 43,613 45,000 Stock issued due to exercise of options 925,000 130,354 Stock issuance for financing, net of costs 4,405,373 6,516,650 Balance at September 30, 2017 89,338,555 $ 16,881,977 Balance at December 31, 2017 90,225,869 $ 18,244,659 Stock issuance for services (i) 641,717 1,238,513 Stock issued due to exercise of options (Note 10) 1,866,996 1,923,922 Stock issuance for financing, net of costs (ii) 1,861,627 3,966,362 Balance at September 30, 2018 94,596,209 $ 25,373,456 i. On May 10, 2018, 641,717 $1,238,513 ii. On May 15, 2018, 255,815 $550,000. June 28, 2018, 1,605,812 $3,452,496. $23,806

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. Stock-based compensation During the three September 30, 2018, 85,000 three September 30, 2017, 427,940 nine September 30, 2018 1,866,996, nine September 30, 2017, 925,000 1,815,000 one The continuity of stock options are as follows: Number of Options Weighted Avg Exercise Price (CDN$) Balance at December 31, 2016 7,975,000 0.84 Stock options exercised on February 21, 2017 (10,000 ) 0.25 Stock options exercised on February 21, 2017 (400,000 ) 0.05 Options issued on February 24, 2017 535,000 1.50 Stock options exercised on May 8, 2017 (7,060 ) 1.50 Stock options cancelled on May 17, 2017 (10,000 ) 1.50 Stock options exercised on May 23, 2017 (80,000 ) 0.25 Stock options exercised on July 6, 2017 (200,000 ) 0.05 Stock options exercised on July 17, 2017 (220,000 ) 0.25 Options issued on August 14, 2017 1,280,000 2.75 Stock options exercised on August 29, 2017 (7,940 ) 1.50 Stock options exercised on December 19, 2017 (25,000 ) 0.25 Stock options exercised on December 19, 2017 (750,000 ) 1.50 Balance at December 31, 2017 8,080,000 1.21 Stock options exercised on January 8, 2018 (124,000 ) 0.25 Stock options exercised on January 26, 2018 (100,000 ) 0.25 Stock options exercised on March 8, 2018 (50,000 ) 0.25 Stock options exercised on March 13, 2018 (176,000 ) 0.25 Stock options exercised on March 22, 2018 (50,000 ) 0.25 Stock options exercised on March 26, 2018 (240,000 ) 0.25 Stock options exercised on March 28, 2018 (325,000 ) 0.25 Stock options exercised on March 29, 2018 (562,996 ) 2.75 Stock options exercised on April 20, 2018 (154,000 ) 0.25 Stock options expired on April 21, 2018 (1,946,000 ) 0.25 Stock options cancelled on June 8, 2018 (100,000 ) 1.50 Stock options cancelled on June 21, 2018 (400,000 ) 1.50 Stock options cancelled on August 14, 2018 (75,000 ) 2.75 Stock options exercised on September 27, 2018 (85,000 ) 1.50 Stock options cancelled on September 28, 2018 (5,000 ) 2.75 Balance at September 30, 2018 3,687,004 1.72 As at September 30, 2018, Grant date Exercise price (CDN$) Number of options issued and outstanding Number of vested options outstanding Weighted avg remaining life (years) December 21, 2016 1.50 2,415,000 2,415,000 0.22 December 21, 2016 1.50 100,000 100,000 0.12 February 24, 2017 1.50 35,000 35,000 0.40 February 24, 2017 1.50 500,000 500,000 0.12 August 14, 2017 (a) 2.75 387,004 387,004 0.87 August 14, 2017 (a) 2.75 250,000 250,000 0.12 The fair value of options granted during the three nine September 30, 2018 December 31, 2017 February 24, 2017 August 14, 2017 (a) August 14, 2017 (b) Volatility 59 % 59 % 83 % Risk-free interest rate 0.81 % 1.22 % 1.22 % Expected life (years) 2 2 1 Dividend yield 0 % 0 % 0 % Common share price CDN $1.35 CDN $2.40 CDN $2.40 Strike price CDN $1.50 CDN $2.75 CDN $2.75 Forfeiture rate nil nil nil The Company recorded nil three September 30, 2018 ( three September 30, 2017 - $675,941 $7,288 nine September 30, 2018 ( nine September 30, 2017 - $161,590 $98,715 $34,608 three September 30, 2018. $1,537,024 $386,898 nine September 30, 2018. Volatility is determined based on volatilities of comparable companies when the Company does not The risk-free rate assumed in valuing the options is based on the Canadian treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield percentage at the date of grant is nil not nil three nine September 30, 2018 ( three September 30, 2017 - $nil

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and contingencies There were no September 30, 2018.

Note 12 - Financial Instruments

Note 12 - Financial Instruments	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	12. Financial instruments (a) Fair values The Company follows ASC topic 820, 820 820 three three three Level 1 Level 2 1 Level 3 The categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. (i) The Company calculates expected volatility based on historical volatility of the Company’s peer group that is publicly traded for options. An increase/decrease in the volatility would have resulted in an increase/decrease in the fair value of the options. The carrying values of cash, trade and other receivable, accounts payable and accrued liabilities and shareholder loans payable approximates their fair values because of the short-term nature of these instruments. (b) Interest rate and credit risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not The Company is also exposed to credit risk at period end from the carrying value of its cash. The Company manages this risk by maintaining bank accounts with a Canadian Chartered Bank. The Company’s cash is not (c) Foreign exchange risk None The Company has balances in Canadian dollars that give rise to exposure to foreign exchange (“FX”) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. For each Canadian dollar balance of $1.0 10% $0.1 (d) Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown. The following are the contractual maturities of the undiscounted cash flows of financial liabilities as at September 30, 2018 December 31, 2017: September 30, 2018 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,280,379 - - - - 1,280,379 1,280,379 - - - - 1,280,379 December 31, 2017 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 828,737 - - - - 828,737 828,737 - - - - 828,737

Note 13 - Segmented Information

Note 13 - Segmented Information	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	13. Segmented information The Company's operations comprise a single reportable segment engaged in the research, development targeting health and wellness solutions for the companion pet. As the operations comprise a single reportable segment, amounts disclosed in the financial statements for loss for the period, depreciation and total assets also represent segmented amounts. In addition, all of the Company's long-lived assets are in the United States of America (“US”). September 30, 2018 December 31, 2017 $ $ Total assets Canada 521,531 3,519,918 US 3,669,115 1,695,904 Total property and equipment US 756,823 371,157

Note 14 - Schedule of Expenses

Note 14 - Schedule of Expenses	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Operating Expenses [Text Block]	14. Schedule of expenses For the three months ended September 30, 2018 For the three months ended September 30, 2017 Research and Development Professional Fees General and Administrative Research and Development Professional Fees General and Administrative Salaries, bonus and benefits $ 164,267 $ - $ 454,786 $ 118,227 $ - $ 1,136,402 Contracted expenditures 259,947 - - 156,980 - - Marketing and investor relations - - 53,996 - - 13,015 Travel and accommodation 8,023 - 36,491 6,425 - 49,532 Insurance 20,855 - 76,903 21,900 - 48,373 License fees - - - - - - Office 6,665 - 82,416 16,701 - 26,803 Consultants 80,425 293,484 - 58,536 246,192 - Regulatory 19,247 - 32,904 25,775 - 28,844 Rent 15,396 - 90,463 12,040 - 38,805 Supplies 55,546 - 6,611 48,911 - 8,951 Total $ 630,371 $ 293,484 $ 834,570 $ 465,495 $ 246,192 $ 1,350,726 For the nine months ended September 30, 2018 For the nine months ended September 30, 2017 Research and Development Professional Fees General and Administrative Research and Development Professional Fees General and Administrative Salaries, bonus and benefits $ 490,706 $ - $ 1,957,341 $ 478,231 $ - $ 2,107,835 Contracted expenditures 968,159 - - 516,275 - 5,610 Marketing and investor relations - - 177,151 - - 116,196 Travel and accommodation 13,360 - 228,359 9,383 - 228,317 Insurance 65,099 - 234,646 59,572 - 132,474 License fees 1,738,513 - - - - - Office 41,312 - 220,823 28,569 - 76,967 Consultants 169,613 1,001,886 - 226,985 942,385 - Regulatory 57,422 - 226,604 77,325 - 100,979 Rent 31,047 - 176,501 31,303 - 121,231 Supplies 190,101 - 21,807 158,536 - 36,750 Total $ 3,765,332 $ 1,001,886 $ 3,243,232 $ 1,586,179 $ 942,385 $ 2,926,361

Note 15 - Capital Risk Manageme

Note 15 - Capital Risk Management	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Capital Risk Management [Text Block]	15. Capital risk management The capital of the Company includes equity, which is comprised of issued common capital stock, additional paid-in capital, and accumulated deficit. The Company's objective when managing its capital is to safeguard the ability to continue as a going concern in order to provide returns for its shareholders, and other stakeholders and to maintain a strong capital base to support the Company's core activities.

Note 16 - Loss Per Share

Note 16 - Loss Per Share	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	16. Loss per share For the three months ended September 30, For the nine months ended September 30, 2018 2017 2018 2017 Numerator Net loss for the period $ 1,910,278 $ 2,080,682 $ 8,226,005 $ 5,501,788 Denominator Weighted average shares - basic 94,514,905 88,844,534 92,534,667 86,708,499 Stock options - - - - Denominator for diluted loss per share 94,514,905 88,844,534 92,534,667 86,708,499 Loss per share - basic and diluted $ (0.02 ) $ (0.02 ) $ (0.09 ) $ (0.06 ) For the above mentioned periods, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted loss per share in the periods presented, as their effect would have been anti-dilutive.

Note 17 - Related Party Transac

Note 17 - Related Party Transactions and Key Management Compensation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	17. Related party transactions and key management compensation Key management personnel are comprised of the Company’s directors and executive officers. In addition to their salaries, key management personnel also receive share-based compensation. Key management personnel compensation is as follows: For the three months ended September 30, For the nine months ended September 30, 2018 2017 2018 2017 Salaries and benefits, including bonuses $ 324,784 $ 329,314 $ 1,046,449 $ 954,311 Stock-based compensation - 598,595 - 749,615 Total $ 324,784 $ 927,909 $ 1,046,449 $ 1,703,926

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of the condensed unaudited interim consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed unaudited interim consolidated financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are: the fair values of financial assets and liabilities; the determination of fair value of stock-based compensation; the useful lives of property and equipment; and forecasting future cash flows for assessing the going concern assumption.
Basis of Measurement [Policy Text Block]	Basis of measurement The condensed unaudited interim consolidated financial statements have been prepared on the historical cost basis except as otherwise noted.
Functional and Reporting Currencies [Policy Text Block]	Functional and reporting currencies The Company’s and subsidiary’s functional currency, as determined by management, is US dollars, which is also the Company’s reporting currency. The accounting policies set out below have been applied consistently to all periods and companies presented in the condensed unaudited interim consolidated financial statements.
Research and Development Expense, Policy [Policy Text Block]	Research and development Research and development costs related to continued research and development programs are expensed as incurred in accordance with ASC topic 730.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Translation of foreign currencies In respect of other transactions denominated in currencies other than the Company and its wholly owned operating subsidiaries’ functional currencies, the monetary assets and liabilities are translated at the period end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. All of the exchange gains or losses resulting from these other transactions are recognized in the condensed unaudited interim consolidated statements of operations and comprehensive loss.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based compensation The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted if the fair value of the goods or services received by the Company cannot be reliably estimated. The Company calculates stock-based compensation using the fair value method, under which the fair value of the options at the grant date is calculated using the Black-Scholes Option Pricing Model, and subsequently expensed over the vesting period of the option. The provisions of the Company's stock-based compensation plans do not The Company estimates forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Earnings Per Share, Policy [Policy Text Block]	Loss per share Basic loss per share (“EPS”) is computed by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of options are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. The dilutive effect of stock options is determined using the treasury stock method. Stock options to purchase common shares of the Company during the period were not nine September 30, 2018
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss The Company follows ASC topic 220. no
New Accounting Pronouncements, Policy [Policy Text Block]	Future accounting pronouncements In February 2016, No. 2016 02, 842 842 December 15, 2018.

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer equipment Furniture and equipment Laboratory equipment Leasehold improvements Total Cost Balance at December 31, 2016 $ 61,598 $ 7,364 $ 243,529 $ 25,672 $ 338,163 Additions 89,557 68,694 2,200 11,285 171,736 Balance at December 31, 2017 151,155 76,058 245,729 36,957 509,899 Additions 11,701 105,821 246,375 250,471 614,368 Disposals - - (139,466 ) (10,937 ) (150,403 ) Balance at September 30, 2018 162,856 181,879 352,638 276,491 973,864 Accumulated depreciation Balance at December 31, 2016 13,858 1,490 29,783 3,998 49,129 Depreciation 28,944 10,355 45,092 5,222 89,613 Balance at December 31, 2017 42,802 11,845 74,875 9,220 138,742 Depreciation 66,405 11,130 42,082 30,703 150,320 Disposals - - (61,546 ) (10,475 ) (72,021 ) Balance at September 30, 2018 109,207 22,975 55,411 29,448 217,041 109,207 22,975 55,411 29,448 217,041 Net book value as at: December 31, 2017 $ 108,353 $ 64,213 $ 170,854 $ 27,737 $ 371,157 September 30, 2018 $ 53,649 $ 158,904 $ 297,227 $ 247,043 $ 756,823

Note 7 - Intangible Assets (Tab

Note 7 - Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Computer software Trademarks Total Cost Balance at December 31, 2016 $ 5,143 $ 16,236 $ 21,379 Additions - - - Balance at December 31, 2017 5,143 16,236 21,379 Additions - - - Balance at September 30, 2018 5,143 16,236 21,379 Accumulated amortization Balance at December 31, 2016 2,428 1,013 3,441 Amortization 1,715 1,082 2,797 Balance at December 31, 2017 4,143 2,095 6,238 Amortization 1,000 810 1,810 Balance at September 30, 2018 5,143 2,905 8,048 Net book value as at: December 31, 2017 $ 1,000 $ 14,141 $ 15,141 September 30, 2018 $ - $ 13,331 $ 13,331

Note 9 - Capital Stock (Tables)

Note 9 - Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Capital Number stock Balance at December 31, 2016 83,964,569 $ 10,189,973 Stock issuance for services 43,613 45,000 Stock issued due to exercise of options 925,000 130,354 Stock issuance for financing, net of costs 4,405,373 6,516,650 Balance at September 30, 2017 89,338,555 $ 16,881,977 Balance at December 31, 2017 90,225,869 $ 18,244,659 Stock issuance for services (i) 641,717 1,238,513 Stock issued due to exercise of options (Note 10) 1,866,996 1,923,922 Stock issuance for financing, net of costs (ii) 1,861,627 3,966,362 Balance at September 30, 2018 94,596,209 $ 25,373,456

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Options Weighted Avg Exercise Price (CDN$) Balance at December 31, 2016 7,975,000 0.84 Stock options exercised on February 21, 2017 (10,000 ) 0.25 Stock options exercised on February 21, 2017 (400,000 ) 0.05 Options issued on February 24, 2017 535,000 1.50 Stock options exercised on May 8, 2017 (7,060 ) 1.50 Stock options cancelled on May 17, 2017 (10,000 ) 1.50 Stock options exercised on May 23, 2017 (80,000 ) 0.25 Stock options exercised on July 6, 2017 (200,000 ) 0.05 Stock options exercised on July 17, 2017 (220,000 ) 0.25 Options issued on August 14, 2017 1,280,000 2.75 Stock options exercised on August 29, 2017 (7,940 ) 1.50 Stock options exercised on December 19, 2017 (25,000 ) 0.25 Stock options exercised on December 19, 2017 (750,000 ) 1.50 Balance at December 31, 2017 8,080,000 1.21 Stock options exercised on January 8, 2018 (124,000 ) 0.25 Stock options exercised on January 26, 2018 (100,000 ) 0.25 Stock options exercised on March 8, 2018 (50,000 ) 0.25 Stock options exercised on March 13, 2018 (176,000 ) 0.25 Stock options exercised on March 22, 2018 (50,000 ) 0.25 Stock options exercised on March 26, 2018 (240,000 ) 0.25 Stock options exercised on March 28, 2018 (325,000 ) 0.25 Stock options exercised on March 29, 2018 (562,996 ) 2.75 Stock options exercised on April 20, 2018 (154,000 ) 0.25 Stock options expired on April 21, 2018 (1,946,000 ) 0.25 Stock options cancelled on June 8, 2018 (100,000 ) 1.50 Stock options cancelled on June 21, 2018 (400,000 ) 1.50 Stock options cancelled on August 14, 2018 (75,000 ) 2.75 Stock options exercised on September 27, 2018 (85,000 ) 1.50 Stock options cancelled on September 28, 2018 (5,000 ) 2.75 Balance at September 30, 2018 3,687,004 1.72
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	Grant date Exercise price (CDN$) Number of options issued and outstanding Number of vested options outstanding Weighted avg remaining life (years) December 21, 2016 1.50 2,415,000 2,415,000 0.22 December 21, 2016 1.50 100,000 100,000 0.12 February 24, 2017 1.50 35,000 35,000 0.40 February 24, 2017 1.50 500,000 500,000 0.12 August 14, 2017 (a) 2.75 387,004 387,004 0.87 August 14, 2017 (a) 2.75 250,000 250,000 0.12
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	February 24, 2017 August 14, 2017 (a) August 14, 2017 (b) Volatility 59 % 59 % 83 % Risk-free interest rate 0.81 % 1.22 % 1.22 % Expected life (years) 2 2 1 Dividend yield 0 % 0 % 0 % Common share price CDN $1.35 CDN $2.40 CDN $2.40 Strike price CDN $1.50 CDN $2.75 CDN $2.75 Forfeiture rate nil nil nil

Note 12 - Financial Instrumen_2

Note 12 - Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities [Table Text Block]	September 30, 2018 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 1,280,379 - - - - 1,280,379 1,280,379 - - - - 1,280,379 December 31, 2017 Less than 3 to 6 6 to 9 9 months Greater than 3 months months months 1 year 1 year Total $ $ $ $ $ $ Third parties Accounts payable and accrued liabilities 828,737 - - - - 828,737 828,737 - - - - 828,737

Note 13 - Segmented Informati_2

Note 13 - Segmented Information (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Long-lived Assets by Geographic Areas [Table Text Block]	September 30, 2018 December 31, 2017 $ $ Total assets Canada 521,531 3,519,918 US 3,669,115 1,695,904 Total property and equipment US 756,823 371,157

Note 14 - Schedule of Expenses

Note 14 - Schedule of Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Operating Expenses [Table Text Block]	For the three months ended September 30, 2018 For the three months ended September 30, 2017 Research and Development Professional Fees General and Administrative Research and Development Professional Fees General and Administrative Salaries, bonus and benefits $ 164,267 $ - $ 454,786 $ 118,227 $ - $ 1,136,402 Contracted expenditures 259,947 - - 156,980 - - Marketing and investor relations - - 53,996 - - 13,015 Travel and accommodation 8,023 - 36,491 6,425 - 49,532 Insurance 20,855 - 76,903 21,900 - 48,373 License fees - - - - - - Office 6,665 - 82,416 16,701 - 26,803 Consultants 80,425 293,484 - 58,536 246,192 - Regulatory 19,247 - 32,904 25,775 - 28,844 Rent 15,396 - 90,463 12,040 - 38,805 Supplies 55,546 - 6,611 48,911 - 8,951 Total $ 630,371 $ 293,484 $ 834,570 $ 465,495 $ 246,192 $ 1,350,726 For the nine months ended September 30, 2018 For the nine months ended September 30, 2017 Research and Development Professional Fees General and Administrative Research and Development Professional Fees General and Administrative Salaries, bonus and benefits $ 490,706 $ - $ 1,957,341 $ 478,231 $ - $ 2,107,835 Contracted expenditures 968,159 - - 516,275 - 5,610 Marketing and investor relations - - 177,151 - - 116,196 Travel and accommodation 13,360 - 228,359 9,383 - 228,317 Insurance 65,099 - 234,646 59,572 - 132,474 License fees 1,738,513 - - - - - Office 41,312 - 220,823 28,569 - 76,967 Consultants 169,613 1,001,886 - 226,985 942,385 - Regulatory 57,422 - 226,604 77,325 - 100,979 Rent 31,047 - 176,501 31,303 - 121,231 Supplies 190,101 - 21,807 158,536 - 36,750 Total $ 3,765,332 $ 1,001,886 $ 3,243,232 $ 1,586,179 $ 942,385 $ 2,926,361

Note 16 - Loss Per Share (Table

Note 16 - Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	For the three months ended September 30, For the nine months ended September 30, 2018 2017 2018 2017 Numerator Net loss for the period $ 1,910,278 $ 2,080,682 $ 8,226,005 $ 5,501,788 Denominator Weighted average shares - basic 94,514,905 88,844,534 92,534,667 86,708,499 Stock options - - - - Denominator for diluted loss per share 94,514,905 88,844,534 92,534,667 86,708,499 Loss per share - basic and diluted $ (0.02 ) $ (0.02 ) $ (0.09 ) $ (0.06 )

Note 17 - Related Party Trans_2

Note 17 - Related Party Transactions and Key Management Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Key Management Personnel Compensation [Table Text Block]	For the three months ended September 30, For the nine months ended September 30, 2018 2017 2018 2017 Salaries and benefits, including bonuses $ 324,784 $ 329,314 $ 1,046,449 $ 954,311 Stock-based compensation - 598,595 - 749,615 Total $ 324,784 $ 927,909 $ 1,046,449 $ 1,703,926

Note 3 - Significant Accounti_2

Note 3 - Significant Accounting Policies (Details Textual) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Other Comprehensive Income (Loss), Net of Tax, Total	$ 0

Note 5 - Prepaid Expenses and_2

Note 5 - Prepaid Expenses and Deposits (Details Textual) - USD ($)	Jul. 31, 2018	Aug. 26, 2016	Sep. 30, 2018	Dec. 31, 2017
Payments for Rent	$ 1,269,073	$ 801,973
Prepaid Rent			$ 509,380	$ 155,220

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Property, Plant and Equipment, Net, Ending Balance		$ 756,823		$ 756,823		$ 371,157
Gain (Loss) on Disposition of Property Plant Equipment, Total	$ (69,382)	(69,382)		(69,382)
Leasehold Improvements [Member]
Property, Plant and Equipment, Net, Ending Balance	462	$ 247,043		$ 247,043		$ 27,737
Equipment [Member]
Property, Plant and Equipment, Net, Ending Balance	77,920
Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset	$ 9,000

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017	Aug. 31, 2018
Cost, Beginning Balance	$ 509,899	$ 338,163
Cost, Additions	614,368	171,736
Cost, Disposals	(150,403)
Cost, Ending Balance	973,864	509,899
Accumulated Depreciation, Beginning Balance	138,742	49,129
Accumulated Depreciation, Depreciation	150,320	89,613
Accumulated Depreciation, Disposals	(72,021)
Accumulated Depreciation, Ending Balance	217,041	138,742
Property, Plant and Equipment, Net, Ending Balance	756,823	371,157
Computer Equipment [Member]
Cost, Beginning Balance	151,155	61,598
Cost, Additions	11,701	89,557
Cost, Disposals
Cost, Ending Balance	162,856	151,155
Accumulated Depreciation, Beginning Balance	42,802	13,858
Accumulated Depreciation, Depreciation	66,405	28,944
Accumulated Depreciation, Disposals
Accumulated Depreciation, Ending Balance	109,207	42,802
Property, Plant and Equipment, Net, Ending Balance	53,649	108,353
Furniture and Fixtures [Member]
Cost, Beginning Balance	76,058	7,364
Cost, Additions	105,821	68,694
Cost, Disposals
Cost, Ending Balance	181,879	76,058
Accumulated Depreciation, Beginning Balance	11,845	1,490
Accumulated Depreciation, Depreciation	11,130	10,355
Accumulated Depreciation, Disposals
Accumulated Depreciation, Ending Balance	22,975	11,845
Property, Plant and Equipment, Net, Ending Balance	158,904	64,213
Laboratory Equipment [Member]
Cost, Beginning Balance	245,729	243,529
Cost, Additions	246,375	2,200
Cost, Disposals	(139,466)
Cost, Ending Balance	352,638	245,729
Accumulated Depreciation, Beginning Balance	74,875	29,783
Accumulated Depreciation, Depreciation	42,082	45,092
Accumulated Depreciation, Disposals	(61,546)
Accumulated Depreciation, Ending Balance	55,411	74,875
Property, Plant and Equipment, Net, Ending Balance	297,227	170,854
Leasehold Improvements [Member]
Cost, Beginning Balance	36,957	25,672
Cost, Additions	250,471	11,285
Cost, Disposals	(10,937)
Cost, Ending Balance	276,491	36,957
Accumulated Depreciation, Beginning Balance	9,220	3,998
Accumulated Depreciation, Depreciation	30,703	5,222
Accumulated Depreciation, Disposals	(10,475)
Accumulated Depreciation, Ending Balance	29,448	9,220
Property, Plant and Equipment, Net, Ending Balance	$ 247,043	$ 27,737	$ 462

Note 7 - Intangible Assets - Fi

Note 7 - Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Cost, Beginning Balance			$ 21,379	$ 21,379	$ 21,379
Cost, Additions
Cost, Ending Balance	$ 21,379		21,379		21,379
Accumulated Amortization, Beginning Balance			6,238	3,441	3,441
Accumulated Amortization, Amortization	431	$ 699	1,810	2,098	2,797
Accumulated Amortization, Ending Balance	8,048		8,048		6,238
Net Book Value	13,331		13,331		15,141
Computer Software, Intangible Asset [Member]
Cost, Beginning Balance			5,143	5,143	5,143
Cost, Additions
Cost, Ending Balance	5,143		5,143		5,143
Accumulated Amortization, Beginning Balance			4,143	2,428	2,428
Accumulated Amortization, Amortization			1,000		1,715
Accumulated Amortization, Ending Balance	5,143		5,143		4,143
Net Book Value					1,000
Trademarks [Member]
Cost, Beginning Balance			16,236	16,236	16,236
Cost, Additions
Cost, Ending Balance	16,236		16,236		16,236
Accumulated Amortization, Beginning Balance			2,095	$ 1,013	1,013
Accumulated Amortization, Amortization			810		1,082
Accumulated Amortization, Ending Balance	2,905		2,905		2,095
Net Book Value	$ 13,331		$ 13,331		$ 14,141

Note 8 - Loan Arrangements (Det

Note 8 - Loan Arrangements (Details Textual) - Loan Arrangement With Shareholder [Member] - USD ($)	Oct. 17, 2017	Sep. 30, 2018
Debt Agreement, Maximum Borrowing Capacity	$ 5,000,000
Debt Instrument, Term	5 years
Debt Agreement, Minimum Borrowing Per Advances	$ 250,000
Debt Instrument, Interest Rate, Stated Percentage	14.00%
Long-term Debt, Total		$ 0

Note 9 - Capital Stock (Details

Note 9 - Capital Stock (Details Textual) - USD ($)	Jun. 28, 2018	May 15, 2018	May 10, 2018	Jun. 28, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018		Sep. 30, 2017
Stock Issued During Period, Value, Issued for Services							$ 1,238,513		$ 45,000
Proceeds from Issuance of Common Stock	$ 3,452,496	$ 550,000				$ 3,320,000	4,002,496		6,570,000
Payments of Stock Issuance Costs				$ 23,806	$ 12,328	$ 19,226	$ 36,135		$ 53,350
Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services			641,717				641,717	[1]	43,613
Stock Issued During Period, Value, Issued for Services			$ 1,238,513				$ 1,238,513	[1]	$ 45,000
Stock Issued During Period, Shares, New Issues	1,605,812	255,815					1,861,627	[2]	4,405,373
[1]	On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.
[2]	On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

Note 9 - Capital Stock - Issued

Note 9 - Capital Stock - Issued and Outstanding Common Shares (Details) - USD ($)	Sep. 27, 2018	Jun. 28, 2018	May 15, 2018	May 10, 2018	Apr. 20, 2018	Mar. 29, 2018	Mar. 28, 2018	Mar. 26, 2018	Mar. 22, 2018	Mar. 13, 2018	Mar. 08, 2018	Jan. 26, 2018	Jan. 08, 2018	Aug. 29, 2017	Jul. 17, 2017	Jul. 06, 2017	May 23, 2017	May 08, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018		Sep. 30, 2017
Number of common shares, beginning balance (in shares)																					90,225,869
Stock issuance for services																					$ 1,238,513		$ 45,000
Stock issued due to exercise of options (in shares)	85,000				154,000	562,996	325,000	240,000	50,000	176,000	50,000	100,000	124,000	7,940	220,000	200,000	80,000	7,060	85,000	427,940	1,866,996		925,000
Stock issued due to exercise of options																					$ 1,537,024		$ 100,198
Stock issuance for financing, net of costs																					$ 3,966,362		$ 6,516,650
Number of common shares, ending balance (in shares)																			94,596,209		94,596,209
Common Stock [Member]
Number of common shares, beginning balance (in shares)																					90,225,869		83,964,569
Capital stock, beginning balance																					$ 18,244,659		$ 10,189,973
Stock issuance for services (in shares)				641,717																	641,717	[1]	43,613
Stock issuance for services				$ 1,238,513																	$ 1,238,513	[1]	$ 45,000
Stock issued due to exercise of options (in shares)																					1,866,996		925,000
Stock issued due to exercise of options																					$ 1,923,922		$ 130,354
Stock issuance for financing, net of costs (in shares)		1,605,812	255,815																		1,861,627	[2]	4,405,373
Stock issuance for financing, net of costs																					$ 3,966,362	[2]	$ 6,516,650
Number of common shares, ending balance (in shares)																			94,596,209	89,338,555	94,596,209		89,338,555
Capital stock, ending balance																			$ 25,373,456	$ 16,881,977	$ 25,373,456		$ 16,881,977
[1]	On May 10, 2018, the Company issued 641,717 common shares in accordance with a development, commercialization and exclusive distribution agreement with Seraph Biosciences, Inc. and recognized $1,238,513 as a research and development expense in the condensed unaudited interim consolidated financial statements.
[2]	On May 15, 2018, the Company issued 255,815 common shares for gross proceeds of $550,000. On June 28, 2018, the Company issued 1,605,812 common shares for gross proceeds of $3,452,496. The Company recorded $23,806 of share issuance costs as an offset to capital stock.

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation (Details Textual) - USD ($)	Sep. 27, 2018	Apr. 20, 2018	Mar. 29, 2018	Mar. 28, 2018	Mar. 26, 2018	Mar. 22, 2018	Mar. 13, 2018	Mar. 08, 2018	Jan. 26, 2018	Jan. 08, 2018	Aug. 29, 2017	Aug. 14, 2017	Jul. 17, 2017	Jul. 06, 2017	May 23, 2017	May 08, 2017	Feb. 24, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	85,000	154,000	562,996	325,000	240,000	50,000	176,000	50,000	100,000	124,000	7,940		220,000	200,000	80,000	7,060		85,000	427,940	1,866,996	925,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												1,280,000					535,000				1,815,000
Allocated Share-based Compensation Expense, Total																		$ 0	$ 675,941	$ 7,288	$ 161,590
Proceeds from Stock Options Exercised																		$ 98,715	$ 60,655	1,537,024	100,198
Stock Issued During Period, Value, Stock Options Exercised																				$ 1,537,024	$ 100,198
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																	0.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																				0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments																				$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Estimated Forfeiture Rate																		0.00%	0.00%	0.00%	0.00%
Additional Paid-in Capital [Member]
Stock Issued During Period, Value, Stock Options Exercised																		$ (34,608)		$ (386,898)	$ (30,156)

Note 10 - Stock-based Compens_4

Note 10 - Stock-based Compensation - Issuance of Stock Options (Details) - $ / shares	Sep. 28, 2018	Sep. 27, 2018	Aug. 14, 2018	Jun. 21, 2018	Jun. 08, 2018	Apr. 21, 2018	Apr. 20, 2018	Mar. 29, 2018	Mar. 28, 2018	Mar. 26, 2018	Mar. 22, 2018	Mar. 13, 2018	Mar. 08, 2018	Jan. 26, 2018	Jan. 08, 2018	Dec. 19, 2017	Aug. 29, 2017	Aug. 14, 2017	Jul. 17, 2017	Jul. 06, 2017	May 23, 2017	May 17, 2017	May 08, 2017	Feb. 24, 2017	Feb. 21, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Number of Options, Options Outstanding (in shares)																										3,687,004		3,687,004		8,080,000	7,975,000
Weighted Avg Exercise Price, Options Outstanding (in CAD per share)																										$ 1.72		$ 1.72		$ 1.21	$ 0.84
Number of Options, Options Exercised (in shares)		(85,000)					(154,000)	(562,996)	(325,000)	(240,000)	(50,000)	(176,000)	(50,000)	(100,000)	(124,000)		(7,940)		(220,000)	(200,000)	(80,000)		(7,060)			(85,000)	(427,940)	(1,866,996)	(925,000)
Weighted Avg Exercise Price, Options Exercised (in CAD per share)	$ 2.75	$ 1.50	$ 2.75	$ 1.50	$ 1.50	$ 0.25	$ 0.25	$ 2.75	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25	$ 0.25		$ 1.50		$ 0.25	$ 0.05	$ 0.25		$ 1.50
Number of Options, Options Issued (in shares)																		1,280,000						535,000					1,815,000
Weighted Avg Exercise Price, Options Issued (in CAD per share)																		$ 2.75						$ 1.50
Number of Options, Options Canceled (in shares)																						(10,000)
Weighted Avg Exercise Price, Options Cancelled (in CAD per share)																						$ 1.50
Stock options expired on April 21, 2018 (in shares)						(1,946,000)
Stock options cancelled on June 8, 2018 (in shares)	(5,000)		(75,000)	(400,000)	(100,000)
Options 1 [Member]
Number of Options, Options Exercised (in shares)																(25,000)									(10,000)
Weighted Avg Exercise Price, Options Exercised (in CAD per share)																$ 0.25									$ 0.25
Options 2 [Member]
Number of Options, Options Exercised (in shares)																(750,000)									(400,000)
Weighted Avg Exercise Price, Options Exercised (in CAD per share)																$ 1.50									$ 0.05

Note 10 - Stock-based Compens_5

Note 10 - Stock-based Compensation - Details of the Issued Stock Options (Details) - $ / shares	Aug. 14, 2017	Feb. 24, 2017	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Weighted Avg Exercise Price, Options Issued (in CAD per share)	$ 2.75	$ 1.50
Number of Options, Options Outstanding (in shares)			3,687,004	8,080,000	7,975,000
December 21, 2016 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 1.50
Number of Options, Options Outstanding (in shares)			2,415,000
Number of Vested Options (in shares)			2,415,000
Weighted Avg Remaining Life (Year)			80 days
December 21, 2016 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 1.50
Number of Options, Options Outstanding (in shares)			100,000
Number of Vested Options (in shares)			100,000
Weighted Avg Remaining Life (Year)			43 days
February 24, 2017 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 1.50
Number of Options, Options Outstanding (in shares)			35,000
Number of Vested Options (in shares)			35,000
Weighted Avg Remaining Life (Year)			146 days
February 24, 2017 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 1.50
Number of Options, Options Outstanding (in shares)			500,000
Number of Vested Options (in shares)			500,000
Weighted Avg Remaining Life (Year)			43 days
August 14, 2017 [Member] | Options 1 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 2.75
Number of Options, Options Outstanding (in shares)			387,004
Number of Vested Options (in shares)			387,004
Weighted Avg Remaining Life (Year)			317 days
August 14, 2017 [Member] | Options 2 [Member]
Weighted Avg Exercise Price, Options Issued (in CAD per share)			$ 2.75
Number of Options, Options Outstanding (in shares)			250,000
Number of Vested Options (in shares)			250,000
Weighted Avg Remaining Life (Year)			43 days

Note 10 - Stock-based Compens_6

Note 10 - Stock-based Compensation - Valuation Assumptions for Fair Value of Options Granted (Details) - $ / shares	Aug. 14, 2017	Feb. 24, 2017
Volatility		59.00%
Risk-free interest rate		0.81%
Expected life (Year)		2 years
Dividend yield		0.00%
Common share price (in CAD per share)		$ 1.35
Strike price (in CAD per share)		$ 1.50
Forfeiture rate
Options 1 [Member]
Volatility	59.00%
Risk-free interest rate	1.22%
Expected life (Year)	2 years
Dividend yield	0.00%
Common share price (in CAD per share)	$ 2.40
Strike price (in CAD per share)	$ 2.75
Options 2 [Member]
Volatility	83.00%
Risk-free interest rate	1.22%
Expected life (Year)	1 year
Dividend yield	0.00%
Common share price (in CAD per share)	$ 2.40
Strike price (in CAD per share)	$ 2.75

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) $ in Thousands	Sep. 30, 2018USD ($)
Operating Leases, Future Minimum Payments Due, Total	$ 0

Note 12 - Financial Instrumen_3

Note 12 - Financial Instruments - Contractual Maturities of Undiscounted Cash Flows of Financial Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounts Payable and Accrued Liabilities, Maturity Less Than 3 Months	$ 1,280,379	$ 828,737
Accounts payable and accrued liabilities, Maturity 3 to 6 Months
Accounts payable and accrued liabilities, Maturity 6 to 9 Months
Accounts payable and accrued liabilities, Maturity 9 to 12 Months
Accounts payable and accrued liabilities, Maturity Greater Than 1 Year
Accounts payable and accrued liabilities	1,280,379	828,737
Contractual Financial Liabilities, Maturity Less Than 3 Months	1,280,379	828,737
Contractual Financial Liabilities, Maturity 3 to 6 Months
Contractual Financial Liabilities, Maturity 6 to 9 Months
Contractual Financial Liabilities, Maturity 9 to 12 Months
Contractual Financial Liabilities, Maturity Greater Than 1 Year
Contractual Financial Liabilities	$ 1,280,379	$ 828,737

Note 13 - Segmented Informati_3

Note 13 - Segmented Information - Long-lived Assets by Geographic Areas (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Assets	$ 4,190,646	$ 5,215,822
Property and equipment	756,823	371,157
CANADA
Assets	521,531	3,519,918
UNITED STATES
Assets	3,669,115	1,695,904
Property and equipment	$ 756,823	$ 371,157

Note 14 - Schedule of Expense_2

Note 14 - Schedule of Expenses - Schedule of Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Research and development	$ 630,371	$ 465,495	$ 3,765,332	$ 1,586,179
Professional fees	293,484	246,192	1,001,886	942,385
General and administrative	834,570	1,350,726	3,243,232	2,926,361
Salaries, Bonus and Benefits [Member]
Research and development	164,267	118,227	490,706	478,231
Professional fees
General and administrative	454,786	1,136,402	1,957,341	2,107,835
Contracted Expenditures [Member]
Research and development	259,947	156,980	968,159	516,275
Professional fees
General and administrative				5,610
Marketing and Investor Relations [Member]
Research and development
Professional fees
General and administrative	53,996	13,015	177,151	116,196
Travel and Accommodation [Member]
Research and development	8,023	6,425	13,360	9,383
Professional fees
General and administrative	36,491	49,532	228,359	228,317
Insurance [Member]
Research and development	20,855	21,900	65,099	59,572
Professional fees
General and administrative	76,903	48,373	234,646	132,474
License Fees [Member]
Research and development			1,738,513
Professional fees
General and administrative
Office [Member]
Research and development	6,665	16,701	41,312	28,569
Professional fees
General and administrative	82,416	26,803	220,823	76,967
Consultant [Member]
Research and development	80,425	58,536	169,613	226,985
Professional fees	293,484	246,192	1,001,886	942,385
General and administrative
Regulatory [Member]
Research and development	19,247	25,775	57,422	77,325
Professional fees
General and administrative	32,904	28,844	226,604	100,979
Rent [Member]
Research and development	15,396	12,040	31,047	31,303
Professional fees
General and administrative	90,463	38,805	176,501	121,231
Supplies [Member]
Research and development	55,546	48,911	190,101	158,536
Professional fees
General and administrative	$ 6,611	$ 8,951	$ 21,807	$ 36,750

Note 16 - Loss Per Share - Loss

Note 16 - Loss Per Share - Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net loss for the period	$ 1,910,278	$ 2,080,682	$ 8,226,005	$ 5,501,788
Weighted average shares - basic (in shares)	94,514,905	88,844,534	92,534,667	86,708,499
Stock options (in shares)
Denominator for diluted loss per share (in shares)	94,514,905	88,844,534	92,534,667	86,708,499
Loss per share - basic and diluted (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.09)	$ (0.06)

Note 17 - Related Party Trans_3

Note 17 - Related Party Transactions and Key Management Compensation - Key Management Personnel Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation	$ 0	$ 675,941	$ 7,288	$ 161,590
Director and Executive Officers [Member]
Salaries and benefits, including bonuses	324,784	329,314	1,046,449	954,311
Stock-based compensation		598,595		749,615
Total	$ 324,784	$ 927,909	$ 1,046,449	$ 1,703,926